Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Paolo Antonio AsciertoEvan J LipsonReinhard DummerJames M G LarkinGeorgina V LongRachel E SanbornVanna Chiarion SileniBrigitte DrenoStéphane DalleDirk SchadendorfMargaret K CallahanMarta NyakasVictoria AtkinsonCarlos Alberto Gomez RocaNaoya YamazakiHussein A TawbiNaomey SarkisDeepti M WaradSonia DolfiPriyam MitraSatyendra SuryawanshiJean-Jacques GrobPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nivolumab and relatlimab had a manageable safety profile and demonstrated durable clinical activity in a proportion of patients with heavily pretreated advanced melanoma with prior progression on anti-PD-(L)1-containing regimens.